Oncopeptides Annual Report for 2017

Stockholm – April 18 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Annual Report for 2017 now is available at the company’s website: www.oncopeptides.com.

For further information, please contact or visit www.oncopeptides.se:

Jakob Lindberg, CEO of Oncopeptides
Cell phone: +46 705 695 471
E-mail:
jakob.lindberg@oncopeptides.se 

Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 708 537 292
E-mail:
rein.piir@oncopeptides.se

The information was submitted through the agency of the contact person above for publication at 17.00 CET on  April 18, 2018.

About Oncopeptides

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo®, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program of Ygalo® is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Tags:

About Us

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate Ygalo®, an alkylating peptide, belonging to a new class of drugs (Peptidase Enhanced Compounds - PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Subscribe